Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Insights Into Non‐Classic Primary Bone Sarcomas in Children, Adolescents, and Young Adults: A French Descriptive Study
Rafael Moisan, Jennifer Wallet, Sébastien Aubert, Pascaline Boudou‐Rouquette, Nathalie Gaspar, Perrine Marec‐Bérard, Estelle Thébaud, Emmanuelle Bompas, Gonzague de Pinieux, Jean‐Luc Jouve, Antoine Italiano, Christine Chevreau, Jean Yves Blay, Cyril Lervat (2025). Insights Into Non‐Classic Primary Bone Sarcomas in Children, Adolescents, and Young Adults: A French Descriptive Study. , 72(10), DOI: https://doi.org/10.1002/pbc.31931.
Article58 days ago88P Head, neck and shoulder desmoid-type fibromatosis: characteristics and outcome of these ultra-rare locations
N. Penel, S. Bonvalot, J. Elices-Diez, A. Italiano, B. Verret, Jenny Kurtz, Pascale Dubray‐Longeras, C. Guillemet, F. Duffaud, François Bertucci, J. Thery, Marie Vanseymortier, E. Bompas, Nelly Firmin, P. Boudou Rouquette, Jennifer Wallet, Sophie Piperno‐Neumann, Thibaud Valentin, Jean Yves Blay, M. Le Deley (2025). 88P Head, neck and shoulder desmoid-type fibromatosis: characteristics and outcome of these ultra-rare locations. , 10, DOI: https://doi.org/10.1016/j.esmoop.2025.104401.
Article58 days agoCO9.4 - Contribution of Q-TWiST and GPC methods for the evaluation of the benefit-risk ratio in a randomised controlled trial. Application to the EREMISS trial.
Clémence Leguillette, S. Salvaggio, Jennifer Wallet, Jean Yves Blay, B. Verret, A. Italiano, N. Penel, M. Le Deley (2025). CO9.4 - Contribution of Q-TWiST and GPC methods for the evaluation of the benefit-risk ratio in a randomised controlled trial. Application to the EREMISS trial.. , 73, DOI: https://doi.org/10.1016/j.jeph.2025.203018.
Article58 days ago2698P Evaluation of the benefit-risk ratio in EREMISS randomized trial using Q-TWiST and GPC methods
N. Penel, Clémence Leguillette, Jennifer Wallet, Jean Yves Blay, B. Verret, A. Italiano, S. Salvaggio, M. Le Deley (2025). 2698P Evaluation of the benefit-risk ratio in EREMISS randomized trial using Q-TWiST and GPC methods. , 36, DOI: https://doi.org/10.1016/j.annonc.2025.08.3309.
Article58 days agoRegorafenib as maintenance therapy after first-line doxorubicin-based chemotherapy in advanced non-adipocytic soft tissue sarcomas patients: a double-blind randomised trial
Nicolas Penel, Antoîne Italiano, Jennifer Wallet, L. Chaigneau, B. Verret, Nelly Firmin, Sarah Watson, Thibaud Valentin, Emmanuelle Bompas, François Bertucci, Mehdi Brahmi, Clémence Hénon, Angélique Brunot, Mariella Spalato Ceruso, Marie Vanseymortier, E Heyman-Decoupigny, Thomas Ryckewaert, Marie‐Cécile Le Deley, Christophe Perrin, Jean Yves Blay (2025). Regorafenib as maintenance therapy after first-line doxorubicin-based chemotherapy in advanced non-adipocytic soft tissue sarcomas patients: a double-blind randomised trial. , 36(8), DOI: https://doi.org/10.1016/j.annonc.2025.03.024.
Article58 days ago